Tamoxifen administered in patients after breast cancer surgery is one of the most effective adjuvant treatments in this pathology. A large number of randomized studies including thousands of patients allowed to quantify the treatment benefits in terms of recurrence, contralateral breast cancer and overall survival rates. The treatment is generally given for more than 2 years. However, the optimal treatment duration is unknown. Uncertainties appeared when adverse effects were described after some years of treatment (e.g. a higher incidence of endometrial adenocarcinoma). New ongoing multicentric trials will clearly define in the next years the optimal duration of this adjuvant treatment.

Type

Journal article

Journal

Rev Med Chil

Publication Date

02/1998

Volume

126

Pages

210 - 217

Keywords

Antineoplastic Agents, Hormonal, Breast Neoplasms, Chemotherapy, Adjuvant, Female, Follow-Up Studies, Humans, Tamoxifen, Time Factors, Treatment Outcome